Industry

BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a virtual fireside chat at the upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference on Wednesday, … [Read more…]

NEW YORK & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apertura Gene Therapy, a biotechnology company leveraging its novel platform technologies for developing genetic medicines to treat debilitating diseases, today announced the appointment of gene therapy executive Joseph La Barge as Chief Executive Officer. La Barge joins Apertura with over 20 years of experience in building and operating life-science companies. … [Read more…]

Triatomic Capital’s Jeff Huber to Join Board of Directors with this Funding BOSTON–(BUSINESS WIRE)–Manifold Bio, a next-generation protein therapeutics company pioneering an in vivo biologics design platform, today announced the close of a $40 million Series A financing round led by Triatomic Capital and joined by new investors Section 32, FPV Ventures, Horizons Ventures, and … [Read more…]

RADNOR, Pa.–(BUSINESS WIRE)–$MRNS #MarinusPharma—Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million. “Upon completion, the sale of the PRV will significantly strengthen … [Read more…]

DANVERS, Mass.–(BUSINESS WIRE)–Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, August 4, 2022, the Company will release financial results for the first quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Thursday, August 4, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief … [Read more…]

Data show correlation between targeted activity in the brain and improvement in motor speed and executive function, providing further validation of Akili’s technology platform and its potential to improve select cognitive impairments across different indications Data also offer preliminary evidence of EVO™ Monitor’s ability to provide rapid mobile assessment of cognitive function BOSTON–(BUSINESS WIRE)–Akili Interactive … [Read more…]

The Harmonic™ trial is a Phase 2 multi-center study focused on never smokers with advanced non-small cell lung cancer (NSCLC) and will begin patient enrollment during Q3 2022. In a previous Phase 3 multi-center clinical trial, a subset of never smoker patients with NSCLC receiving LP-300 with chemotherapy showed increased overall and two-year survival of … [Read more…]

LAWRENCE, Kan.–(BUSINESS WIRE)–Endpoints News, the biopharma industry’s leading source for daily news and analysis, announced today the expansion of its editorial team with the appointments of Jared Whitlock as Features Editor and Aayushi Pratap as News Reporter. Jared Whitlock has written for a variety of publications, including The New York Times, WIRED, STAT and the … [Read more…]

FDA Defers Action on BLA Until Required Inspections Can Be Completed Due to COVID Travel Restrictions, Inspections Could Not Be Completed During Review Period CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and … [Read more…]

The hospital is one of only a few institutions in the country to allow parents to stay in the same room with their child during the treatment. LOS ANGELES–(BUSINESS WIRE)–Children with high-risk neuroblastoma can now access a specialized, targeted radiation treatment called MIBG therapy at Children’s Hospital Los Angeles—one of the largest neuroblastoma programs in … [Read more…]